We are pleased to invite you to the webinar titled ‘New Evolution in the Management of Atopic Dermatitis’ presented by Prof. Kristian Reich.
Prof. Kristian Reich will discuss:
- why targeting JAK1/2 in atopic dermatitis improves atopic dermatitis skin signs and symptoms.
- what implications targeting JAK1/2 might have on safety signals.
- the importance of interpreting safety concerns as well as JAK selectivity in the context of the safety profile in clinical trials.
- what implication Baricitinib molecule characteristics beyond JAK inhibition have on clinical practice.
FREE
Free